Last reviewed · How we verify
NCT06204341: HYPOPRIME
Towards Optimal Treatment for High Risk Prostate Cancer
NA trial testing HYPOPRIME treatment in High Risk Prostate Carcinoma in 207 participants. Currently enrolling.
18 December 2032
Quick facts
| Lead sponsor | Haaglanden Medical Centre |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 207 |
| Start date | 2 January 2024 |
| Primary completion | 18 December 2032 |
| Estimated completion | 18 December 2032 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- HYPOPRIME treatment
Conditions studied
- High Risk Prostate Carcinoma — all drugs for High Risk Prostate Carcinoma →
Sponsor
Haaglanden Medical Centre — full company profile →
Who can join
18 and older, male only, with High Risk Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments. * patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation) * the tumor will get a higher dose * androgen deprivation therapy will be reduced as much al possible preventing side effects Researchers will compare oncological outcome and toxicity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
External beam focal boost radiotherapy to intraprostatic lesions in prostate cancer: a scoping review.
Liu Y, Qin S, Ren X, Bai Y, et al · · 2026 · PMID 42093677 · DOI 10.1016/j.phro.2026.100980
Verify or expand the search:
- PubMed search for NCT06204341
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for High Risk Prostate Carcinoma
Currently open trials in the same condition.
- NCT06384222 — Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone · Phase 2 · recruiting
- NCT06461793 — Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Pati · Phase 2 · recruiting
- NCT05004285 — Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis · Phase 3 · active not recruiting
Other Haaglanden Medical Centre trials
Trials by the same sponsor.
- NCT05851989 — Study on Prognosis of Acutely Ruptured Intracranial Aneurysms · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06204341 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haaglanden Medical Centre
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204341.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing